Passage BIO, Inc.
A clinical-stage genetic medicines company developing therapies for CNS disorders.
PASG | US
Overview
Corporate Details
- ISIN(s):
- US7027121000
- LEI:
- Country:
- United States of America
- Address:
- ONE COMMERCE SQUARE, 19103 PHILADELPHIA
- Website:
- https://www.passagebio.com/
Description
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Passage BIO, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Passage BIO, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Passage BIO, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
